Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what the future holds and what if any long-term global effects may result from this latest contagion. Therefore, this paper is about expanding on two themes that are of importance to the successful long-term operation of global ...

The recent announcement of Biogen’s potential breakthrough in finding a drug that may finally deliver benefits to Alzheimer’s patients represents a milestone in treating this dreadful disease. It also should serve as a reminder and an important lesson to those who wish to undermine this engine of innovation on the incentives needed to bring novel medicines to the marketplace. Unfortunately, a ...

The importation of drugs from lower-priced countries, like Canada, was an idea brought up during the Clinton Administration as a way for consumers to bypass the high cost of prescription drugs in the US. The effect of allowing importation is essentially about the imposition of a foreign drug price control on the US market. The economic analysis of the adverse effects of price controls on R&D ...

Many pharma companies have begun shifting their R&D portfolios to the development of new cancer drugs. A pharma company recently announced a bold new cancer drug R&D portfolio strategy where the company will focus on early-stage cancers over late-stage (advanced) cancers for new drug development. This shift in focus goes against the standard target development paradigm where companies ...

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroeconomists who think they have mastered the science and art of counter-cyclical monetary and fiscal policies. The macroeconomic environment for pharma companies is an exogenous factor beyond the capability of any individual ...

Axtria periodically receives questions from pharma clients on whether they should proceed with conducting a sales contest (under the general category of special incentive programs or SIPs), and if so, how should a successful sales contest be designed in order to achieve desired outcomes? Companies annually spend an enormous amount of money on sales contests according to recent estimates. Yet, ...

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial growth, and generate cost efficiencies. The pharma industry has recently seen a flurry of significant M&As with more surely to follow. This white paper highlights the importance that M&As will have on the future ...

The Trump administration announced earlier this year a proposal to eliminate rebates to PBMs in the Medicare and parts of the Medicaid programs effective January 1, 2020. The Trump administration made eliminating rebates a significant part of the American Patients First blueprint initiative launched in May 2018 to reduce out-of-pocket prescription drug costs. Most pharma experts predicted this ...

The short answer to this question is most definitely “yes,” and probably more important now than ever before. Annual pharma company spending on their sales force is still among the single largest line item in the budget, and according to promotion-response and marketing-mix analyses, remains a significant driver of sales revenue and contribution. The changes in the pharma environment from a ...